A Practical Guide to Pan Coating and Scale-Up - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Practical Guide to Pan Coating and Scale-Up
An understanding of the pan-coating process based on first principles can support successful scale up.


Equipment and Processing Report


There are various theories about how to scale up a solid dosage coating operation in a pan coater. This article provides a basic process understanding and scale-up theory based on first principles.

The coating process shown in Figure 1 has multiple, simultaneous, ongoing exchange processes. The first is a heat exchange between the inlet process air and the coater metal body, spray droplets, and tablets. The second is a mass exchange between the material sprayed and the inlet air stream, tablets, and coating pan.


There are certain losses (e.g., heat loss to the metal body and the environment), however, that cannot be characterized easily. An approximate mass and energy balance for the coating process in an equilibrium state can be calculated as shown in Equations 1–3, where H = enthalpy and m = mass.

The heat balance is shown in Equation 1:


The mass balance for the solvent is shown in Equation 2:


The mass balance for the solids sprayed is shown in Equation 3:


As with any theoretical analysis, there are assumptions built into the model described above. For example:


•Leftover material in lines are not considered.
•Heat loss to equipment body and environment are not considered.
•Any unrecoverable mass loss in the process is not accounted for.

This model can be used to calculate process efficiency and efficiency of the inlet air heat capacity. Efficiency of coating will generally improve as the process is scaled up because the bed depth will be increased, thus increasing the heat exchange between the process air and the tablets.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Equipment and Processing Report,
Click here